Barinthus Biotherapeutics plc

Equities

BRNS

US91864C1071

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 14:44:17 17/07/2024 BST			5-day change	1st Jan Change
1.55 ^USD	+0.32%		+8.01%	-57.99%

06-21	Top Premarket Gainers	MT
06-13	Barclays Adjusts Price Target on Barinthus Biotherapeutics to $3 From $7, Maintains Overweight Rating	MT

Vaccitech Limited announced that it has received £20 million in funding from GV, Sequoia Capital China, Oxford Sciences Innovation, Neptune Investment Management Limited

January 14, 2018

Vaccitech Limited announced that it has received £20 million in its series A round of funding co-led by new investor GV and Sequoia Capital China on January 15, 2018. The transaction also involved participation from existing investor Neptune Investment Management and Oxford Sciences Innovation plc a fund managed by Oxford Sciences Innovation. The company received £30 million in funding till date.

Latest news about Barinthus Biotherapeutics plc

Top Premarket Gainers	06-21	MT
Barclays Adjusts Price Target on Barinthus Biotherapeutics to $3 From $7, Maintains Overweight Rating	06-13	MT
Barinthus Bio to Cut Workforce 25% to Focus on Hepatitis, Celiac Treatments After Positive Data; Shares Rise After Hours	06-12	MT
Barinthus Biotherapeutics plc Plans to Priority on the Development of VTP-300 in Chronic Hepatitis B Virus Infection, or CHB, and VTP-1000 in Celiac Disease	06-12	CI
Barthus Biotherapeutics plc Announces Updated Data from Two Clinical Trials in People with Chronic Hepat B	06-06	CI
Arbutus Biopharma Says Imdusiran Plus VTP-300 Therapy Lowers HBsAg Levels in Trial	06-06	MT
Top Premarket Gainers	06-06	MT
Barinthus Biotherapeutics plc Reports Earnings Results for the First Quarter Ended March 31, 2024	05-13	CI
Barinthus Biotherapeutics plc Appoints Leon Hooftman as Chief Medical Officer, Effective June 3, 2024	05-01	CI
Barinthus Cervical Lesions Treatment Study Meets Primary Objective -- Shares Rise After Hours	04-18	MT
BarinthuBarinthus Biotherapeutics plc Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus Infections	04-18	CI
ADRs Advance; Connect Biopharma Climbs 19%	04-05	DJ
ADRs End Higher, Aesthetic Medical International Holdings Group Ltd. Climbs 35.5%	04-03	DJ
Barinthus Biotherapeutics plc Reports Earnings Results for the Full Year Ended December 31, 2023	03-20	CI
Arbutus Biopharma Corporation and Barinthus Biotherapeutics plc Present Preliminary Data from Phase 2A Clinical Trial Combining Imdusiran with VTP-300 at AASLD	11-09	CI
Barinthus Biotherapeutics plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
CanSino Biologics Enrolls First Case in Recombinant Zoster Vaccine Trial in Canada	11-09	MT
Barinthus Biotherapeutics plc(NasdaqGM:BRNS) added to NASDAQ Composite Index	11-08	CI
Vaccitech plc(NasdaqGM:VACC) dropped from NASDAQ Composite Index	11-06	CI
ADRs End Higher; TC Biopharm PLC Climbs 19%	30/10/23	DJ
ADRs Advance, Akso Health Group Rises 29.6%	06/10/23	DJ
ADRs End Higher; Dunxin Financial Holdings Ltd. Climbs 11.7%	04/10/23	DJ
ADRs Slump; Turbo Energy S.A. Declines 37.7%	25/09/23	DJ
Health Care Up on Defensive Bets -- Health Care Roundup	25/09/23	DJ
Sector Update: Health Care Stocks Advancing Late Afternoon	25/09/23	MT

Chart Barinthus Biotherapeutics plc

Duration

Period

More charts

Company Profile

Barinthus Biotherapeutics plc, formerly Vaccitech plc, is a clinical-stage biopharmaceutical company. It is focused on developing novel T cell immunotherapeutic that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. Its four platform technologies include ChAdOx, MVA, SNAP-TI, and SNAP-CI. It is advancing a pipeline of five product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer, and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer.

Sector

Biotechnology & Medical Research

Calendar

07/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.545 USD

Average target price

5.8 USD

Spread / Average Target

+275.40%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
BARINTHUS BIOTHERAPEUTICS PLC	-57.99%	60.31M
MODERNA, INC.	+23.71%	47.96B
IQVIA HOLDINGS INC.	+1.95%	42.45B
LONZA GROUP AG	+44.59%	41.47B
ALNYLAM PHARMACEUTICALS, INC.	+28.19%	31.6B
ICON PUBLIC LIMITED COMPANY	+21.69%	28.63B
CELLTRION, INC.	-6.35%	28.03B
UNITED THERAPEUTICS CORPORATION	+52.76%	14.56B
MEDPACE HOLDINGS, INC.	+49.28%	14.14B
BIO-TECHNE CORPORATION	+3.84%	12.58B

Other Biotechnology & Medical Research